Montelucaste Teva (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelucaste Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance treatment of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in patients who require long‑term control.

GNH USA supplies Montelucaste Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelucaste Teva, a leukotriene receptor antagonist, is used to manage conditions driven by cysteinyl leukotriene activity. - Asthma (maintenance therapy): improves long‑term control and reduces exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelucaste Teva is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain or dyspepsia. - Cough or throat irritation. - Nasopharyngitis (common cold‑like symptoms). - Dizziness or somnolence. - Mild rash or itching.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Angioedema: swelling of lips, tongue or face. - Hematologic abnormalities: eosinophilia or neutropenia.

Before initiating therapy, clinicians should consider several safety aspects. - Hypersensitivity: avoid in patients with known allergy to montelukast or any tablet excipients. - Hepatic impairment: monitor liver function tests in patients with existing liver disease. - Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited. - Pediatric use: dose selection must follow prescriber guidance based on age and weight. - Drug interactions: review concomitant medications for possible pharmacokinetic effects. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Montelucast Teva may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may reduce montelukast exposure and efficacy. - Concomitant use with other leukotriene modifiers (e.g., zafirlukast): increased risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Oral contraceptives: may slightly increase plasma levels of estrogen components. - Phenobarbital: may modestly lower montelukast concentrations. - Ritonavir or other protease inhibitors: may increase montelukast levels, watch for side effects.